These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31713367)

  • 1. An 81-Year-Old Male with Advanced Dementia and Recurrent Cerebrovascular Events: Is There a Place for Cannabidiol Therapy?
    Hermush V; Ore L
    Isr Med Assoc J; 2019 Nov; 21(11):759-760. PubMed ID: 31713367
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Mallada Frechín J
    Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
    Celius EG; Vila C
    Brain Behav; 2018 May; 8(5):e00962. PubMed ID: 29761015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
    Gras A; Broughton J
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):771-779. PubMed ID: 26750641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cannabis medicines in Norway--the basis for approval].
    Gramstad L; Sagabråten AS
    Tidsskr Nor Laegeforen; 2012 Dec; 132(23-24):2598-9. PubMed ID: 23338087
    [No Abstract]   [Full Text] [Related]  

  • 6. Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD).
    Meyer T; Funke A; Münch C; Kettemann D; Maier A; Walter B; Thomas A; Spittel S
    BMC Neurol; 2019 Sep; 19(1):222. PubMed ID: 31493784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness and safety of tolperisone in spasticity following cerebral stroke: randomized, double-blind, placebo-controlled trial].
    Lipták J
    Ideggyogy Sz; 2013 Jul; 66(7-8):283-4. PubMed ID: 23971362
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduction in spasticity in stroke patient with paraffin therapy.
    Wang J; Yu P; Zeng M; Gu X; Liu Y; Xiao M
    Neurol Res; 2017 Jan; 39(1):36-44. PubMed ID: 27876449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
    Vaney C; Heinzel-Gutenbrunner M; Jobin P; Tschopp F; Gattlen B; Hagen U; Schnelle M; Reif M
    Mult Scler; 2004 Aug; 10(4):417-24. PubMed ID: 15327040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C; Davies P; Mutiboko IK; Ratcliffe S;
    Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?
    Metz L; Page S
    Lancet; 2003 Nov; 362(9395):1513. PubMed ID: 14615102
    [No Abstract]   [Full Text] [Related]  

  • 12. High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis.
    Baricich A; Grana E; Carda S; Santamato A; Cisari C; Invernizzi M
    J Neural Transm (Vienna); 2015 Sep; 122(9):1283-7. PubMed ID: 25724294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrathecal baclofen for spasticity caused by thrombotic stroke.
    Gwartz BL
    Am J Phys Med Rehabil; 2001 May; 80(5):383-7. PubMed ID: 11327562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Delta-9-tetrahydrocannabinol-cannabidiol in the treatment of spasticity in chronic spinal cord injury: a clinical experience].
    Grao-Castellote C; Torralba-Collados F; Gonzalez LM; Giner-Pascual M
    Rev Neurol; 2017 Oct; 65(7):295-302. PubMed ID: 28929471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is new in multiple sclerosis spasticity research? Poster session highlights.
    Ghezzi A
    Neurodegener Dis Manag; 2016 Dec; 6(6s):45-47. PubMed ID: 27874498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Russo EB
    Neurology; 2003 Feb; 60(4):729-30; author reply 729-30. PubMed ID: 12601130
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of medical-grade cannabis in patients non-responders to Nabiximols.
    Saccà F; Pane C; Carotenuto A; Massarelli M; Lanzillo R; Florio EB; Brescia Morra V
    J Neurol Sci; 2016 Sep; 368():349-51. PubMed ID: 27538663
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
    Oreja-Guevara C
    Rev Neurol; 2012 Oct; 55(7):421-30. PubMed ID: 23011861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
    Marinelli L; Mori L; Canneva S; Colombano F; Currà A; Fattapposta F; Bandini F; Capello E; Abbruzzese G; Trompetto C
    Int Clin Psychopharmacol; 2016 Jul; 31(4):232-9. PubMed ID: 27003093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.